EFFICACY AND SAFETY OF GUSELKUMAB TN PATIENTS WITH ACTIVE PSORIATIC ARTHRITIS WHO DEMONSTRATED INADEQUATE RESPONSE TO TUMOR NECROSIS FACTOR INHIBITION: WEEK 24 RESULTS OF A PHASE 3B, RANDOMIZED, CONTROLLED STUDY

被引：0
|
作者：
Coates, Laura C. [1 ]
Gossec, Laure [2 ]
Theander, Elke [3 ]
Bergmans, Paul [4 ]
Neuhold, Marlies [5 ]
Karyekar, Chetan S. [6 ]
Shawi, May [6 ]
Noel, Wim [5 ]
Schett, Georg [7 ]
McInnes, Iain B. [8 ]
机构：
[1] Univ Oxford, Nuffield Dept Orthopaed Rheumatol & Musculoskelet, Oxford, England
[2] Sorbonne Univ, Dept Rheumatol, Paris, France
[3] Janssen Sci Affairs LLC, Dept Immunol, Solna, Sweden
[4] Janssen, Dept Biostat, Breda, Netherlands
[5] Janssen Sci Affairs LLC, Dept Immunol, Brussels, Belgium
[6] Janssen Global Serv LLC, Dept Immunol, Horsham, PA USA
[7] FAU Erlangen Nurnberg, Dept Internal Med 3, Nurnberg, Germany
[8] Univ Glasgow, Dept Immunol, Glasgow, Lanark, Scotland
来源：
JCR-JOURNAL OF CLINICAL RHEUMATOLOGY | 2021年 / 27卷
关键词：
DOUBLE-BLIND;
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
PANLAR2021
引用
收藏
页码：S106 / S107
页数：2
相关论文
共 50 条
  • [41] Comparative efficacy and safety of biologic agents in patients with active rheumatoid arthritis and inadequate response to tumor necrosis factor inhibitors: A Bayesian network meta-analysis of randomized controlled trials
    Sung, Yoon-Kyoung
    Lee, Young Ho
    INTERNATIONAL JOURNAL OF CLINICAL PHARMACOLOGY AND THERAPEUTICS, 2022, 60 (01) : 13 - 23
  • [42] The effect of guselkumab on inhibiting radiographic progression in patients with active psoriatic arthritis: study protocol for APEX, a Phase 3b, multicenter, randomized, double-blind, placebo-controlled trial
    Christopher T. Ritchlin
    Laura C. Coates
    Philip J. Mease
    Désirée van der Heijde
    Jiao Song
    Yusang Jiang
    May Shawi
    Alexa P. Kollmeier
    Proton Rahman
    Trials, 24
  • [43] The effect of guselkumab on inhibiting radiographic progression in patients with active psoriatic arthritis: study protocol for APEX, a Phase 3b, multicenter, randomized, double-blind, placebo-controlled trial
    Ritchlin, Christopher T.
    Coates, Laura C.
    Mease, Philip J.
    van der Heijde, Desiree
    Song, Jiao
    Jiang, Yusang
    Shawi, May
    Kollmeier, Alexa P.
    Rahman, Proton
    TRIALS, 2023, 24 (01)
  • [44] GUSELKUMAB EFFICACY IN ADULT PATIENTS WITH ACTIVE PSORIATIC ARTHRITIS BY BASELINE DEMOGRAPHIC AND DISEASE CHARACTERISTICS: POOLED RESULTS OF TWO PHASE 3, RANDOMIZED, PLACEBO-CONTROLLED STUDIES
    Deodhar, Atul
    Mease, Philip J.
    Boencke, Wolf-Henning
    Tesser, John
    Schiopu, Elena
    Chakravarty, Soumya D.
    Kollmeier, Alexa P.
    Hsia, Elizabeth C.
    Xu, Xie L.
    Shawi, May
    Jiang, Yusang
    Sheng, Shihong
    Agarwal, Prasheen
    Merola, Joseph F.
    McInnes, Iain B.
    Ritchlin, Christopher T.
    JCR-JOURNAL OF CLINICAL RHEUMATOLOGY, 2021, 27 : S108 - S109
  • [45] Efficacy and safety of Guselkumab through 2 years: Results from a phase 3, randomized, double-blind, placebo-controlled study conducted in biologic-naive patients with active psoriatic arthritis
    McInnes, I.
    Rahman, P.
    Gottlieb, A.
    Hsia, E.
    Kollmeier, A.
    Xu, X.
    Sheng, S.
    Jiang, Y.
    Shawi, M.
    Chakravarty, S.
    van der Heijde, D.
    Mease, P.
    EXPERIMENTAL DERMATOLOGY, 2021, 30 : 38 - 38
  • [46] Guselkumab Efficacy in Adult Patients with Active Psoriatic Arthritis by Baseline Demographic and Disease Characteristics: Pooled Results of Two Phase 3, Randomized, Placebo-Controlled Studies
    Deodhar, Atul
    Mease, Philip
    Boehncke, Wolf-Henning
    Tesser, John
    Schiopu, Elena
    Chakravarty, Soumya
    Kollmeier, Alexa
    Hsia, Elizabeth
    Xu, Xie
    Shawi, May
    Jiang, Yusang
    Sheng, Shihong
    Agarwal, Prasheen
    Merola, Joseph
    McInnes, Iain
    Ritchlin, Christopher
    ARTHRITIS & RHEUMATOLOGY, 2020, 72
  • [47] EFFICACY AND SAFETY OF IXEKIZUMAB IN PATIENTS WITH ACTIVE PSORIATIC ARTHRITIS: 52 WEEK RESULTS FROM A PHASE 3 STUDY (SPIRIT-P1)
    Mease, P. J.
    Okada, M.
    Kishimoto, M.
    Shuler, C. L.
    Carlier, H.
    Lin, C. -Y.
    Mou, J.
    Moriarty, S. R.
    Lee, C. H.
    Gladman, D. D.
    ANNALS OF THE RHEUMATIC DISEASES, 2016, 75 : 96 - 96
  • [48] Bimekizumab Treatment in Biologic DMARD-Naive Patients with Active Psoriatic Arthritis: 52-Week Efficacy and Safety Results from a Phase 3, Randomized, Placebo-Controlled, Active Reference Study
    Ritchlin, Christopher
    Coates, Laura
    McInnes, Iain
    Mease, Philip J.
    Merola, Joseph
    Tanaka, Yoshiya
    Asahina, Akihiko
    Gossec, Laure
    Gottlieb, Alice
    Thaci, Diamant
    Ink, Barbara
    Assudani, Deepak
    Bajracharya, Rajan
    Shende, Vish
    Coarse, Jason
    Landewe, Robert
    ARTHRITIS & RHEUMATOLOGY, 2022, 74 : 4533 - 4536
  • [49] SUSTAINED GUSELKUMAB RESPONSE IN PATIENTS WITH ACTIVE PSORIATIC ARTHRITIS REGARDLESS OF BASELINE DEMOGRAPHIC AND DISEASE CHARACTERISTICS: POOLED RESULTS THROUGH WEEK 52 OF TWO PHASE 3, RANDOMIZED, PLACEBO-CONTROLLED STUDIES
    Ritchlin, C. T.
    Mease, P. J.
    Boehncke, W. H.
    Tesser, J.
    Schiopu, E.
    Chakravarty, S. D.
    Kollmeier, A.
    Hsia, E. C.
    Xu, X. L.
    Shawi, M.
    Jiang, Y.
    Sheng, S.
    Merola, J. F.
    McInnes, I.
    Deodhar, A.
    ANNALS OF THE RHEUMATIC DISEASES, 2021, 80 : 1291 - 1292
  • [50] Efficacy and safety of guselkumab in patients with psoriasis who have an inadequate response to ustekinumab: results of the randomized, double-blind, phase III NAVIGATE trial
    Langley, R. G.
    Tsai, T. -F.
    Flavin, S.
    Song, M.
    Randazzo, B.
    Wasfi, Y.
    Jiang, J.
    Li, S.
    Puig, L.
    BRITISH JOURNAL OF DERMATOLOGY, 2018, 178 (01) : 114 - 123
12345